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Abstract
Background: Rates of cardiovascular disease are higher among HIV-infected patients as a result of the complex
interplay between traditional risk factors, HIV-related inflammatory and immunologic changes, and effects of
antiretroviral therapy (ART). This study prospectively evaluated changes in cardiovascular biomarkers in an
underrepresented, racially diverse, HIV-1-infected population receiving abacavir/lamivudine as backbone therapy.
Methods: This 96-week, open-label, randomized, multicenter study compared once-daily fosamprenavir/ritonavir
1400/100 mg and efavirenz 600 mg, both with ABC/3TC 600 mg/300 mg, in antiretroviral-naïve, HLA-B*5701-
negative adults without major resistance mutations to study drugs. We evaluated changes from baseline to weeks
4, 12, 24, 48, and 96 in interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), soluble vascular adhesion
molecule-1 (sVCAM-1), d-dimer, plasminogen, and fibrinogen. Biomarker data were log-transformed before analysis,
and changes from baseline were described using geometric mean ratios.
Results: This study enrolled 101 patients (51 receiving fosamprenavir/ritonavir; 50 receiving efavirenz): 32% female,
60% African American, and 38% Hispanic/Latino; 66% (67/101) completed 96 weeks on study. At week 96, levels of
IL-6, sVCAM-1, d-dimer, fibrinogen, and plasminogen were lower than baseline in both treatment groups, and the
decrease was statistically significant for sVCAM-1 (fosamprenavir/ritonavir and efavirenz), d-dimer (fosamprenavir/
ritonavir and efavirenz), fibrinogen (efavirenz), and plasminogen (efavirenz). Values of hs-CRP varied over time in
both groups, with a significant increase over baseline at Weeks 4 and 24 in the efavirenz group. At week 96, there
was no difference between the groups in the percentage of patients with HIV-1 RNA <50 copies/mL
(fosamprenavir/ritonavir 63%; efavirenz 66%) by ITT missing-equals-failure analysis. Treatment-related grade 2–4
adverse events were more common with efavirenz (32%) compared with fosamprenavir/ritonavir (20%), and median
lipid concentrations increased in both groups over 96 weeks of treatment.
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Conclusions: In this study of underrepresented patients, treatment with abacavir/lamivudine combined with either
fosamprenavir/ritonavir or efavirenz over 96 weeks, produced stable or declining biomarker levels except for hs-CRP,
including significant and favorable decreases in thrombotic activity (reflected by d-dimer) and endothelial activation
(reflected by sVCAM-1). Our study adds to the emerging data that some cardiovascular biomarkers are decreased
with initiation of ART and control of HIV viremia.
Trial registration: ClinicalTrials.gov identifier NCT00727597
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Underrepresented
Background
Cardiovascular disease (CVD) is the leading cause of
death among Americans [1], is of particular import-
ance in HIV-infected patients because it may be exac-
erbated by the chronic inflammation and dyslipidemia
seen in this patient population [2,3]. Compared with
uninfected controls, rates of myocardial infarction
(MI) and sudden cardiac death are higher among pa-
tients with HIV [4-6]. These outcomes are the result
of a complex interplay between traditional CVD risk
factors, HIV-related inflammatory and immunologic
changes, and the effects of antiretroviral therapy
(ART) [2,3,7].
In the United States, racial and ethnic minorities
are disproportionately affected by the HIV/AIDS epi-
demic. Many of the traditional risk factors for CVD
such as hypertension, diabetes, and obesity are higher
in the African-American population [8]. Clinical trials
demographics often do not reflect the diverse nature
of the HIV-positive population in the United States.
Given the relatively low rates of CVD endpoints, such
as myocardial infarction or stroke, many studies use
biomarkers of inflammation, thrombogenesis, and/or
endothelial activation to evaluate the effects of HIV
and/or ART on the cardiovascular system [2-4,9-16].
Data on the predictive value of individual cardiovas-
cular biomarkers in HIV-infected patients are still
emerging [2,3], and, to date, no study has prospect-
ively examined these biomarkers in an exclusively
non-white population.
The present study was a randomized trial compar-
ing ritonavir-boosted fosamprenavir (FPV/r) versus
EFV, both in combination with abacavir/lamivudine
(ABC/3TC), in an ART-naïve, HIV-infected popula-
tion that is often underrepresented in clinical trials in
the United States. The primary endpoint was a meas-
ure of tolerability, and the study included a prospect-
ive, real-time evaluation of changes of pre-specified
cardiovascular biomarkers over 96 weeks. The final,
96-week analysis of the trial with a focus on cardio-
vascular biomarker data is described in this report.
Methods
Study design
This randomized, open-label, multi-centered, pilot study
enrolled patients ≥18 years of age who were ART-naïve
(≤14 days of treatment with any ART), HLA-B*5701-
negative, and had a screening HIV-1 RNA >5000 copies/
mL. Patients were required to be of minority race or eth-
nicity. Females of child-bearing potential could not be
pregnant or breastfeeding at screening and had to agree
to use a suitable form of contraception, including abstin-
ence, double barrier method, or intrauterine device,
throughout the study. Hormonal contraception was not
recommended for female patients taking FPV/r because
of decreased efficacy of contraception and increased risk
of hepatic transaminase elevation.
Patients were excluded if they had an active or acute
CDC Clinical Category C event (AIDS-defining illness)
within 28 days of screening or had chronic hepatitis B
infection (HBsAg+), hepatitis C infection requiring ac-
tive treatment, clinically-relevant pancreatitis or hepa-
titis, AST or ALT >5× upper limit of normal, any grade
4 laboratory abnormality, hemoglobin <8 g/dL, platelet
count <50,000/mm3, or calculated creatinine clearance
<50 mL/min via Cockcroft-Gault equation at screening.
Use of immunomodulators (e.g., interleukins, inter-
ferons, cyclosporine), any vaccinations, systemic cyto-
toxic chemotherapy, or investigational therapy was
prohibited within 28 days of study entry. Patients were
also excluded if their screening HIV-1 genotype indi-
cated the presence of specific mutations. In the reverse
transcriptase (RT) region, exclusionary mutations were
those associated with resistance to abacavir, lamivudine,
or efavirenz (K65R, L74V, K103N, Y115F, Y181C/I,
Y188C/L/H, G190S/A), or a combination of two or more
thymidine analog mutations (M41L, D67N, K70R,
K219Q or E) that included changes at either L210 or
T215. Within the protease region, exclusionary muta-
tions were those associated with resistance to
fosamprenavir or ritonavir (I50V, I54L/M, I84V) or the
combination of V32I + I147V. There were no restrictions
on screening CD4 cell count.
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All patients provided written informed consent to par-
ticipate in the study, and the protocol was approved by
the institutional review board for each study site. Eligible
patients were randomized 1:1 to receive either FPV
1400 mg once daily (LEXIVAW, ViiV Healthcare, Re-
search Triangle Park, NC) plus ritonavir 100 mg once
daily (NorvirW, Abbott Laboratories, North Chicago, IL)
or EFV 600 mg once daily (SustivaW, Bristol-Myers
Squibb, Princeton, NJ). All patients also received ABC
600 mg + 3TC 300 mg once daily (EPZICOMW, ViiV
Healthcare, Research Triangle Park, NC). Randomization
was stratified by screening HIV-1 RNA <100,000 and
≥100,000 c/mL.
For the virology HIV-1 genotypic analysis, virologic
failure was defined as having either virologic non-
response (failure to achieve HIV-1 RNA <400 c/mL by
Week 24) or confirmed virologic rebound (reduction of
HIV RNA to <400 c/mL by Week 24 with a subsequent
increase to ≥400 c/mL on two consecutive occasions 2
to 4 weeks apart.) In the case of clinically-suspected
hypersensitivity to ABC, patients were permitted to sub-
stitute ABC/3TC with another suitable dual nucleoside/
nucleotide RT inhibitor combination chosen by the site
investigator and remained in the study.
Measurements
Clinical, safety, and laboratory evaluations were
performed at screening, baseline, and at weeks 2, 4, 8,
12, 24, 36, 48, 60, 72, 84, and 96 including measure-
ments of plasma HIV-1 RNA, CD4 cell count,
hematology, and blood chemistry. HIV-1 RNA was mea-
sured using the standard or ultrasensitive Roche
Amplicor HIV-1 Monitor assay (Roche Diagnostics,
Branchburg, New Jersey). A fasting lipid panel was done
at baseline and every 24 weeks thereafter through week
96. All laboratory tests were performed centrally by
Quest Diagnostics (Valencia, California, USA). Adverse
events (AEs) and laboratory toxicities were graded using
the 2004 Division of AIDS Toxicity Grading Scale.
Cardiovascular biomarker measurements
Biomarkers were assessed in real-time using whole
blood, plasma, or serum samples collected at baseline
and at weeks 4, 12, 24, 48, and 96. Six biomarkers were
assessed including high-sensitivity C-reactive protein
[hs-CRP] and interleukin-6 [IL-6] which are associated
with inflammation; d-dimer, plasminogen, and fibrino-
gen which are associated with thrombogenesis; and
sVCAM-1 which is associated with endothelial activa-
tion. Biomarkers were assayed centrally by Quest Diag-
nostics (Valencia, California, USA). sVCAM-11 and IL-6
were analyzed by quantitative sandwich ELISA; plas-
minogen by double antibody ELISA; fibrinogen by
photo-optical method; d-dimer by immunoturbidimetry;
and hs-CRP by fixed-time nephelometry. All assays were
performed according to the manufacturers’ recommen-
dations and used their normal ranges.
Endpoints
The pre-specified primary endpoint of this study was the
time to switch of comparator drugs (FPV/r or EFV) or
time to development of any treatment-related grade 3–4
AE. Pre-specified secondary endpoints included change
from baseline in biomarkers of cardiovascular risk; mea-
sures of virologic efficacy; incidence, severity, and caus-
ality of adverse events and laboratory abnormalities; and
change from baseline in CD4 cell count and fasting
lipids. Patients experiencing virologic failure were also
evaluated for treatment-emergent viral resistance
mutations.
Statistical analysis
A sample size of 100 patients was planned for this pilot
study based on practical considerations. Analyses were
performed using the intent-to-treat exposed (ITT-E)
population that included any enrolled patient who took
at least one dose of study medication. Biomarker data
was log-transformed prior to analysis (due to the highly
skewed nature of the data), and the change from base-
line was assessed using geometric mean ratios with 95%
confidence intervals.
Efficacy results were assessed using missing or discon-
tinuation equals failure (MD = F) analyses, in which
missing assessments were considered failures, and ob-
served analyses, in which missing assessments at any
scheduled time point were considered unevaluable and
were not imputed. The primary endpoint was compared
using the log-rank test between the two treatment
groups. Virologic, immunologic, and safety results were
described using summary statistics.
Results
Patient characteristics and accountability
This study, which enrolled 101 patients (51 on FPV/r; 50
on EFV), ran from July 2008 (first patient first visit)
through March 2011 (last patient last visit). Baseline char-
acteristics are shown in Table 1. The number of female
patients and the racial/ethnic distribution was similar
between the two treatment groups. At screening, the per-
centage of patients with HIV RNA ≥100,000 c/mL was
similar between groups, but more patients in the FPV/r-
containing group had CD4 cell counts <200 cells/mm3
(41% FPV/r; 34% EFV). Cardiovascular risk factors
were generally similar between the two groups. Sixty-
six percent of patients completed 96 weeks on study
(Table 2). In both groups, the most common reasons
for premature discontinuation were lack of efficacy and
lost to follow-up.
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Primary endpoint
The primary endpoint of this study was the time to
switch of comparator drugs (FPV/r or EFV) or develop-
ment of any treatment-related grade 3/4 AE. In the
FPV/r-containing group, 4/51 (8%) of patients reached
the latter endpoint compared with 6/50 (12%) in the
EFV-containing group (P = 0.656). Of the 4 patients in
the FPV/r-containing group, 1 switched from FPV/r to
EFV after 14 days due to an adverse event, 1 had grade 3
hypertriglyceridemia at day 57 on treatment, 1 had a
fatal cardiac arrest at day 200, and 1 had grade 3 wors-
ening hyperlipidemia at day 340. The cardiac arrest oc-
curred shortly after the Week 24 study visit in a 49-year
old Central/South Asian male, non-smoker, with a his-
tory of hypercholesterolemia and uncontrolled hyperten-
sion; on autopsy, death was attributed to atherosclerotic
coronary artery disease resulting from 95% narrowing of
the left anterior descending coronary artery by necrotic
plaque. In the EFV-containing group, 3 of 6 patients
Table 1 Baseline patient demographics, characteristics, and medical history
FPV/r + ABC/3TC (n = 51) EFV + ABC/3TC (n = 50)
Median age, years (range) 34.0 (18–79) 33.5 (19–55)
Female, n (%) 16 (31%) 16 (32%)
Race/ethnicity, n (%)
African American, non-Hispanic 29 (57%) 33 (66%)
Hispanic, non-African American 18 (35%) 13 (26%)
African American and Hispanic 3 (6%) 4 (8%)
Asian 1 (2%) 0
Median plasma HIV-1 RNA, log10 copies/mL 4.96 4.82
≥100,000 copies/mL, n (%) 22 (43%) 20 (40%)
Median CD4 cell count, cells/mm3 (range) 237.0 (19–1061) 272.5 (19–699)
<200 cells/mm3, n (%) 21 (41%) 17 (34%)
<50 cells/mm3, n (%) 3 (6%) 7 (14%)
Positive hepatitis C serology 5 (10%) 5 (10%)
CDC classification for HIV infection, n (%)
Category A 40 (78%) 43 (86%)
Category B 4 (8%) 7 (14%)
Category C 7 (14%) 0
Framingham risk score <5%*, n (%) 28 (78%) 28 (88%)
Diabetes type II, n (%) 3 (6%) 1 (2%)
Hypercholesterolemia, n (%) 17 (33%) 14 (28%)
Hypertension, n (%) 9 (18%) 12 (24%)
Tobacco use
Never smoked, n (%) 26 (51%) 19 (38%)
Current smoker, n (%) 20 (39%) 20 (40%)
Former smoker, n (%) 5 (10%) 11 (22%)
Years smoked, median (range)† 10 (2–39) 10 (0–33)
*FPV/r, n = 36; EFV, n = 32. Framingham scores were calculated only in non-diabetic individuals aged 30 years or older. †FPV/r, n = 24; EFV, n = 30.
Abbreviations: ABC/3TC abacavir/lamivudine, CDC Centers for Disease Control and Prevention, EFV efavirenz, FPV/r fosamprenavir/ritonavir.





ITT:Exposed population, n 51 50
Completed 96 weeks on study, n (%) 34 (67%) 33 (66%)
Discontinued study, n (%) 17 (33%) 17 (34%)
Adverse event 3 (6%) 2 (4%)
Lack of efficacy 5 (10%) 5 (10%)
Non-compliance with protocol
treatment
3 (6%) 2 (4%)
Lost to follow-up 6 (12%) 6 (12%)
Withdrew consent 0 2 (4%)
Abbreviations: ABC/3TC abacavir/lamivudine, EFV efavirenz,
FPV/r fosamprenavir/ritonavir, ITT intent-to-treat.
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experienced grade 3 AEs (rash at day 13, acute pancrea-
titis at day 33, and high cholesterol at day 337) and 3
switched from EFV to FPV/r (days 31, 327, and 463) for
adverse events. There was no apparent relationship be-
tween the primary endpoint and baseline viral load.
Virologic and immunologic responses
There was no difference between treatment groups in
the percentage of patients who achieved HIV RNA <50
c/mL at Week 96 using either an ITT -:MD = F or an
observed analysis (Figure 1). Patients with screening
HIV-1 RNA ≥100,000 c/mL had higher rates of viral
suppression at Week 96 by ITT -:MD = F than patients
with screening HIV-1 RNA <100,000 c/mL (Figure 1
inset). Over the 96-week study, the median change from
baseline in CD4 cell count was +186 cells/mm3 (inter-
quartile range: 136 to 311 cells/mm3) in the FPV/r group
and +235 cells/mm3 (range: 137 to 294 cells/mm3) in
the EFV group.
For the virology analysis, by week 24, all on-study sub-
jects had virologically suppressed to <400 copies/ml.
Confirmed virologic failure occurred in 7 patients (14%)
taking FPV/r and 6 patients (12%) taking EFV. In the
FPV/r-containing group, the following treatment-
emergent viral mutations in RT were observed at viro-
logic failure: M184V (in virus from 2 patients); while
virus from another patient developed a treatment-
emergent secondary protease mutation V77I (per
IAS-USA guidelines). In the EFV-containing group, the
following treatment-emergent viral mutations in RT
were observed at virologic failure: M184I/M (in virus
from 1 patient), K65R (virus from 1 patient), and K103N
(virus from 2 patients). Interestingly, virus from 1 pa-
tient experiencing virologic failure while taking EFV also
developed several treatment-emergent secondary PI-
associated mutations.
Safety and tolerability
Treatment-related serious AEs occurred in 2 patients
taking FPV/r (cardiac arrest and suspected drug hyper-
sensitivity to ABC) and in 3 patients taking EFV (acute
pancreatitis, depression, and suspected drug hypersensi-
tivity to ABC). Through Week 96, 20% (10/51) of pa-
tients taking FPV/r and 32% (16/50) taking EFV
experienced treatment-related grade 2–4 AEs. The most
common AEs (FPV/r vs EFV) were rash (2% vs 8%), diz-
ziness (0% vs 8%), and hypercholesterolemia (4% vs 4%).
Three patients in each group (6%) experienced
treatment-related grade 3–4 adverse events (only hyper-
cholesterolemia occurred in >1 patient). Treatment-
emergent grade 3–4 laboratory abnormalities emerged
in 31% (16/51) of patients taking FPV/r and 24% (12/50)
of patients taking EFV; the most common abnormalities
involved cholesterol, creatine kinase, and total
neutrophils.
Median concentrations of total, LDL, and HDL choles-
terol and triglycerides increased over 96 weeks of treat-
ment in both groups (Figure 2), but none of the median
values exceeded the maximum concentrations consid-
ered within normal limits established by the National
0 2 4 8 12 24 36 48 60 72 84 96





Observed n (FPV/r) 51 47 49 48 48 47 45 42 41 39 37 33
Observed n (EFV) 50 47 49 50 50 47 42 42 41 36 35 33
Figure 1 Virologic response (% of patients with HIV-1 RNA <50 copies/mL) over 96 weeks. Virologic response by screening HIV-1 RNA.
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Cholesterol Education program (NCEP). At Week 96,
median change from baseline (range) in total/HDL chol-
esterol ratio was −0.03 (−2.38, 2.77) for the FPV/r group
and −0.22 (−2.64, 2.04) for the EFV group.
Cardiovascular biomarkers
At Week 96, plasminogen, sVCAM, d-dimer, and fi-
brinogen levels decreased significantly from baseline in
the EFV group (by 39%, 42%, 39%, and 12%, respectively)
while sVCAM and d-dimer decreased significantly from
baseline in the FPV/r group (by 48% and 37%, respect-
ively) (Table 3).
Over 96 weeks of treatment, there was no statistically
significant difference between the FPV/r- and EFV-
containing groups at any time point for any of the 6
studied biomarkers. However, statistically significant
changes were observed in some of the biomarkers when
each treatment group was compared with baseline. The
inflammatory biomarker hs-CRP (Figure 3A) increased
during the first 4 weeks of treatment in both groups, but
returned to baseline values in the FPV/r group. In the
EFV group, hs-CRP levels remained elevated for the dur-
ation of the study, with the increase reaching statistical
significance at Weeks 4 and 24. Conversely, levels of the
inflammatory biomarker interleukin-6 (Figure 3B) were
lower than baseline at all time points in both treatment
groups. This difference reached statistical significance
only for the FPV/r group at Week 48. Levels of sVCAM-
1 (Figure 3C), a biomarker of endothelial activation, and
d-dimer (Figure 3D), a thrombotic biomarker, were sig-
nificantly lower than baseline at all time points for both
treatment groups. Fibrinogen (Figure 3E), another
thrombotic biomarker, showed no change over time in
the FPV/r group but decreased in the EFV group, with
the difference reaching statistical significance at Weeks
12, 24, 48, and 96. The final thrombotic biomarker,
plasminogen (Figure 3F), was unchanged over the first
12 weeks on therapy in both treatment groups. At Week
24, plasminogen levels increased in both groups,
reaching statistical significance for FPV/r. Between
Weeks 24 and 96, plasminogen levels decreased in both
groups, with the difference reaching statistical signifi-
cance for EFV at Week 96.
Discussion
This study prospectively investigated changes in inflam-
matory, thrombotic, and endothelial activation bio-
markers among mostly African-American and Hispanic
patients randomized to receive either a boosted protease
inhibitor or a non-nucleoside reverse transcriptase in-
hibitor, each with a backbone of ABC/3TC. Over
96 weeks, except for hs-CRP, biomarker levels generally
remained stable or declined overall, with statistically sig-
nificant declines observed in d-dimer and sVCAM-1 in
both groups, and in plasminogen and fibrinogen in the
EFV group.
Overall, this study comprising a racially diverse, under-
represented patients, showed no evidence of decreased
virologic or immunologic response to either a FPV/r or
EFV-based ART with an ABC/3TC backbone, when
compared with studies performed in less diverse patient
populations. Previous data on race and virologic out-
come are conflicting, but several studies [17-22] have
documented a decrease in the efficacy of EFV among
people of African descent that was not observed here.
Few patients (8% and 12%) in this diverse population
reached the primary study endpoint in either treatment
group, and there was no apparent relationship between
the primary endpoint and race, sex, or baseline viral
load. Rates of virologic suppression were also similar
between the two groups, and patients with screening
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Figure 2 Median fasting lipid concentrations at baseline and at 96 weeks.
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HIV-1 RNA <50 copies/mL at Week 96 than patients
with screening HIV-1 RNA <100,000 c/mL because of
higher dropout rates among patients in the lower viral
load strata in both treatment groups. The higher drop-
out rates observed for the lower viral load strata may be
due to chance given the small sample size of this study.
Other randomized clinical trials of treatment-naïve pa-
tients have included FPV/r or EFV in combination with
ABC/3TC once daily, but, to our knowledge, this study
is the first to compare these regimens directly.
There was one fatality in this study. The 49-year old
male patient in the FPV/r arm with pre-existing hyper-
cholesterolemia and uncontrolled hypertension had a
fatal cardiac arrest after 24 weeks of study and autopsy
results confirmed atherosclerotic coronary artery disease
with 95% narrowing of the left anterior descending cor-
onary artery. Previous observational studies have linked
ritonavir-boosted protease inhibitors and abacavir to the
development of myocardial infarctions [23-25]. More re-
cent observational studies and meta-analyses have not
shown an association between abacavir use and in-
creased risk of cardiovascular complications [26-28].
HIV treatment guidelines now endorse the use of pro-
spective HLA-B*5701 screening in patients before initiat-
ing an ABC-containing regimen to reduce the risk of
developing a abacavir hypersensitivity reaction [29]. In
the present study, two patients who were of African-
American and mixed races, discontinued study after
developing symptoms that were thought to be possibly
related to abacavir hypersensitivity reaction. Symptoms
resolved 7 to 9 days after discontinuation of study regi-
mens. It is noteworthy that in the ARIES trial, which
was a large, multicenter study also conducted in the
United States, the incidence of clinically suspected
abacavir hypersensitivity reaction in HLA-B*5701–nega-
tive patients during the first 30 weeks was 0.8% [30].
However, when these patients underwent abacavir skin-
patch testing (a research tool not for clinical use) at least
6 weeks after symptom resolution, 0% had a positive
skin-patch test, indicating that they did not have im-
munologically confirmed abacavir hypersensitivity
reaction.
In this study, which evaluated exclusively patients
from racial and ethnic minority populations, higher
levels of hs-CRP were observed in the EFV + ABC/3TC
group compared with baseline, although the difference
was statistically significant only at Weeks 4 and 24, while
short-term, non-significant increases from baseline were
observed for hs-CRP levels in the FPV/r + ABC/3TC
group. Our results are generally consistent with previous
studies which have shown hs-CRP to be unchanged or
increased with ART initiation. In ACTG5095, a double-
blind comparison of zidovudine/3TC + EFV and zidovu-
dine/3TC/ABC + EFV, a post-hoc analysis of 196
patients with HIV-1 RNA <50 copies/mL at Weeks 24
and 96 found that hs-CRP was not statistically different
between baseline and Week 96 [11]. Similar results were
observed in a post-hoc analysis of HEAT, a study com-
paring ABC/3TC and TDF/FTC in combination with
ritonavir-boosted lopinavir [12]. At Week 96, hs-CRP
decreased modestly from baseline in both treatment
groups with no statistical difference observed between
the groups; no data were reported regarding the statis-
tical significance of the changes relative to baseline. Fi-
nally, ACTG A5224s which evaluated biomarkers in 244
patients with available stored plasma samples, variability
in hs-CRP response was noted over time and between
treatment groups [14]. Consistent with our study, hs-
CRP was significantly higher than baseline at Weeks 24
and 96 (the only time points measured) in the EFV arm
but hs-CRP levels did not vary significantly from base-
line in the boosted protease inhibitor arm.
A number of factors may explain the variability in hs-
CRP response. One reason proposed may be due to hep-
atocyte dysfunction attributed to HIV infection [14].
Our findings may also reflect genetic or societal risk fac-
tors associated with the study population. In contrast to
some of the previously mentioned studies which have
some minority representation, this study was fully
recruited with a diverse patient population. Furthermore,
the health risk factors observed in this cohort may have
been greater since half of the enrolled subjects were
current or former smokers with a median smoking his-
tory of 10 years, and a considerable proportion of the
enrolled subjects had health issues including hyperten-
sion, and hypercholesterolemia. Given these consider-
ations, hs-CRP may not be a reliable biomarker of
Table 3 Geometric mean ratios (week 96 to baseline) and
95% confidence intervals
Biomarker (no. of samples
per arm)
ABC/3TC + FPV/r ABC/3TC + EFV
hs-CRP 0.99 1.59
(n = 34, 32) (0.56, 1.74) (0.99, 2.56)
Plasminogen 0.73 0.61*
(n = 34, 31) (0.52, 1.02) (0.44, 0.85)
sVCAM-1 0.52* 0.58*
(n = 35, 32) (0.46, 0.58) (0.53, 0.64)
d-dimer 0.63* 0.61*
(n = 35, 31) (0.47, 0.84) (0.48, 0.78)
Interleukin-6 0.77 0.89
(n = 35, 32) (0.53, 1.14) (0.58, 1.36)
Fibrinogen 1.02 0.88*
(n = 33, 30) (0.93, 1.13) (0.78, 0.99)
* P < 0.05.































































































































B. Interleukin-6 (inflammatory)A. hs - CRP (inflammatory)
n (FPV/r) = 51 49 48 47 42 34
n (EFV) = 50 50 50 47 42 32
n (FPV/r) = 51 49 48 47 42 35
































































F. Plasminogen (thrombotic)E. Fibrinogen (thrombotic)
0 4 12 24 48 96
0 4 12 24 48 960 4 12 24 48 96
n (FPV/r) = 51 49 48 47 41 35
n (EFV) = 50 50 50 47 42 32
n (FPV/r) = 51 49 48 47 42 35
n (EFV) = 50 50 50 46 42 31
0 4 12 24 48 96
n (FPV/r) = 49 47 46 45 40 33
n (EFV) = 50 47 50 47 42 30
n (FPV/r) = 51 49 48 47 42 34



























Figure 3 Change from baseline in cardiovascular biomarkers (expressed as geometric mean ratios) over 96 weeks. Inflammatory
biomarkers: A = hs-CRP, B = interleukin-6. Endothelial activation biomarker: C = sVCAM-1. Thrombotic biomarkers: D = d-dimer, E = fibrinogen,
F = plasminogen.
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inflammation in HIV-infected individuals as it is in HIV-
negative individuals [31].
Decreases in IL-6 and sVCAM-1 in this population of
racial and ethnic minorities initiating ARV appear gener-
ally consistent with results noted in previous random-
ized clinical trials of ART-naïve patients. In this study,
values for IL-6 decreased from baseline in both treat-
ment groups, but the change never reached statistical
significance by Week 96. In the HEAT study, IL-6 also
decreased between baseline and Weeks 48 and 96, with
similar declines in both treatment groups [12]. In ACTG
A5224s, IL-6 also declined over time, and the changes
from baseline to Week 96 were statistically significant in
all 4 treatment groups [14]. Importantly, increased IL-6
was shown to be associated with a higher mortality and
more cardiovascular events as seen in the SMART study
[32]. In our study, sVCAM-1 significantly decreased
from baseline at all time points in both treatment
groups. Results from HEAT were similar, with a 50% de-
cline in sVCAM-1 levels in both treatment groups
between baseline and Week 96 (no p-values reported)
[12]. Similarly, in ACTG A5224s, sVCAM-1 decreased
significantly from baseline to Week 96 in all treatment
groups [14].
None of the three randomized trials in ARV-naïve pa-
tients (ACTG5095, HEAT, ACTG5224s) investigated
changes in d-dimer, fibrinogen, or plasminogen. How-
ever, data from observational cohorts support similar
trends for all 3 biomarkers compared with changes ob-
served in this study [9,13,32-35]. In particular, the
SMART study found significantly lower d-dimer levels in
patients taking combination ART for the previous
12 months compared with patients who were off therapy
[32]. Importantly, increases in d-dimer have been shown
to be associated with the higher mortality and cardiovas-
cular events reported in the SMART study [32].
A key limitation of this study is that the clinical signifi-
cance of the biomarker findings is unclear, and the study
did not assess the association between the biomarkers
and more clinical evidence of endothelial dysfunction
such as changes of flow-mediated dilation [36,37]. Other
limitations of this study include the open-label design
and modest sample size. Strengths of this study include
its randomized design, the 96-week follow-up period of
the study, and real-time analysis of the biomarkers in a
racially diverse HIV-infected population with a sizable
proportion of female study participants.
Conclusions
In this study of primarily African-Americans and His-
panics patients typically underrepresented in clinical tri-
als, ART initiation with either FPV/r or EFV, in
combination with ABC/3TC resulted in high levels of vi-
rologic suppression in subjects who continued in the
study through 96 weeks, with consistent and favorable
decreases in thrombotic activity, as reflected by d-dimer
changes, and in endothelial activation, as reflected by
sVCAM-1 changes. Except for hs-CRP, concentrations of
other biomarkers generally remained stable or declined
overall, with statistically significant declines observed in
plasminogen and fibrinogen in the EFV group. Our
study adds to the emerging data that some biomarkers
are decreased with ARV therapy and control of HIV
viremia. Additional studies are needed to further clarify
the clinical significance of these findings and further elu-
cidate whether biomarkers can be used for risk stratifica-
tion in identifying patients that most benefit from
aggressive management of CVD risk.
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